BioVie Inc. is a US-based clinical stage biotech company that discovers, develops, and commercializes drug therapies, including BIV201 for chronic liver cirrhosis and NE3107 for Alzheimer's disease and Parkinson's disease. They also have a pre-clinical stage NE3107 product for multiple myeloma and prostate cancer. BioVie was previously known as NanoAntibiotics and was established in 2013 in Carson City, Nevada.